34. 神経線維腫症 Neurofibromatosis Clinical trials / Disease details
臨床試験数 : 133 / 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05005845 (ClinicalTrials.gov) | September 20, 2021 | 2/8/2021 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas | Cutaneous Neurofibroma;Neurofibromatosis 1 | Drug: NFX-179 gel;Drug: Vehicle gel | NFlection Therapeutics, Inc. | NULL | Active, not recruiting | 18 Years | N/A | All | 199 | Phase 2 | United States |
| 2 | NCT04435665 (ClinicalTrials.gov) | August 21, 2020 | 8/6/2020 | NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas | Neurofibromatosis 1;Cutaneous Neurofibroma | Drug: NFX-179 Gel;Drug: Vehicle Gel | NFlection Therapeutics, Inc. | NULL | Completed | 18 Years | N/A | All | 48 | Phase 2 | United States |